Article
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
PloS one - 1 Jan 2012
Shoji Keiko, Oda Katsutoshi, Kashiyama Tomoko, Ikeda Yuji, Nakagawa Shunsuke, Sone Kenbun, Miyamoto Yuichiro, Hiraike Haruko, Tanikawa Michihiro, Miyasaka Aki, Koso Takahiro, Matsumoto Yoko, Wada-Hiraike Osamu, Kawana Kei, Kuramoto Hiroyuki, McCormick Frank, Aburatani Hiroyuki, Yano Tetsu, Kozuma Shiro, Taketani Yuji
Abstract excerpt
The PI3K (phosphatidylinositol-3-kinase)/mTOR (mammalian target of rapamycin) pathway is frequently activated in endometrial cancer through various PI3K/AKT-activating genetic alterations. We examined the antitumor effect of NVP-BEZ235--a dual PI3K/mTOR inhibitor--and RAD001--an mTOR inhibitor--in 13 endometrial cancer cell lines, all of which possess one or more alterations in PTEN, PIK3CA, and K-Ras. We also...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.